Please assess the completion status of the following clinical trial:

Trial Title: INtraoperative photoDYnamic Therapy of GliOblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient male or female ≥18 years~2. General status (WHO) of Performance status 0, 1 or 2~3. Probable glioblastoma according to clinical and radiological criteria,~4. whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology,~5. Decision to treat the patient as part of the Clinical trial also taken in neuro-oncology RCP (Multidisciplinary consultation meeting)~6. Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical check-up sufficient to insure a post-operative state with normal daily life~7. Clinical neuro-oncological monitoring and long-term MRI scheduled at the hospital CHRU of Lille, center of reference of the region~8. Patient able to understand and sign voluntarily Informed consent~9. Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol~10. Women of child-bearing potential should benefit of an effective contraception~11. For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5-ALA~12. Patient assigned to an heath insurance~Exclusion Criteria:~1. Contraindications to 5-ALA (Gliolan®) and to per-operative PhotoDynamic Therapy perPDT:~2. Contraindications to 5-ALA~   * Porphyria~  * Taking photosensitizer treatment~  * Severe renal or hepatic impairment~  * Bilirubin\> 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)\> 2.5 x Maximum. rates~  * Creatinine clearance \<30 mL / min;~  * Non-compliance with the rules of prevention of the transient risk of cutaneous photosensitization~3. Contraindications to surgery~4. Contraindications to magnetic resonance imaging (MRI)~5. Treatment with an experimental drug within 30 Days prior to the start of the study~6. Clinical follow-up impossible to perform for psychological, familial, social or geographical reasons,~7. Legal incapacity (persons deprived of their liberty or Guardianship or guardianship),~8. Pregnant or nursing women~9. Refusal to participate or sign the consent of the study~10. Soy allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- perPDT (Type: EXPERIMENTAL): Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.

Based on this trial design, predict the completion outcome and termination type (if applicable).